POLB Stock Overview
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.
Poolbeg Pharma PLC Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.046|
|52 Week High||UK£0.12|
|52 Week Low||UK£0.04|
|1 Month Change||3.33%|
|3 Month Change||-17.70%|
|1 Year Change||-54.63%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-56.74%|
Recent News & Updates
Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|POLB||GB Pharmaceuticals||GB Market|
Return vs Industry: POLB underperformed the UK Pharmaceuticals industry which returned -2% over the past year.
Return vs Market: POLB underperformed the UK Market which returned -14.6% over the past year.
|POLB Average Weekly Movement||9.0%|
|Pharmaceuticals Industry Average Movement||6.7%|
|Market Average Movement||5.3%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: POLB is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: POLB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
|POLB fundamental statistics|
Is POLB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|POLB income statement (TTM)|
|Cost of Revenue||UK£0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0062|
|Net Profit Margin||0.00%|
How did POLB perform over the long term?See historical performance and comparison